StockNews.AI
RGNX
StockNews.AI
78 days

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

1. RGNX announces webcast for interim data on RGX-202 for Duchenne muscular dystrophy. 2. Webcast features principal investigator, Dr. Aravindhan Veerapandiyan. 3. Event scheduled for June 5, 2025, highlighting pivotal trial data. 4. RGX-202 is part of RGNX's advanced gene therapy pipeline. 5. Success could bolster RGNX's position in the biotech market.

5m saved
Insight
Article

FAQ

Why Bullish?

Webcast on promising trial data could enhance investor confidence and interest. Historical examples show that positive interim results can lead to significant stock upticks.

How important is it?

The interim data webcast is a significant corporate event that investors will closely follow. Positive results could drive strong sentiment and trading activity in RGNX shares.

Why Long Term?

Long-term implications depend on RGX-202 approval and market adoption after positive trial results. Such advancements can lead to lasting price appreciation, similar to other biotech successes.

Related Companies

REGNAVXSNVS
Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial , /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast to discuss new interim functional data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202, the company's next-generation investigational gene therapy for the treatment of Duchenne muscular dystrophy. The webcast will feature AFFINITY DUCHENNE principal investigator Aravindhan Veerapandiyan, M.D., Arkansas Children's Hospital. Webcast detailsTitle: AFFINITY DUCHENNE® Trial of RGX-202: Phase I/II Interim Functional DataDate/Time: Thursday, June 5, 2025, at 8:00 a.m. EDT Access: The live webcast can be accessed here and in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.REGENXBIO.com. Contacts: Dana CormackCorporate Communications[email protected]  Investors:George E. MacDougallInvestor Relations[email protected] SOURCE REGENXBIO Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News